Treats CMV retinitis. Sold as Foscavir. Every FDA application for this active ingredient: 1 branded and 7 generic.
As of Nov 15, 2026, FDA lists 8 applications for Foscarnet Sodium (sold as Foscavir), first approved Sep 27, 1991, with 3 new uses approved and 0 published complete response letters.
| FOSCARNET SODIUM | Part B | $172K | New | 105 |
| Foscarnet Sodium | Part D | $30K | -3% | 0 |
| CMV-CMI in csCMVi After HSCTCytomegalovirus Infections, Hematopoietic Stem Cell Transplantation (HSCT) · The First Affiliated Hospital of Soochow University | — | Recruiting | Jul 7, 2026 |
| Letermovir Prophylaxis in Children With EBV-Positive T/NK-Cell Lymphoproliferative Disease and Refractory/Relapsed EBV-Associated Hemophagocytic LymphohistiocytosisEBV-associated T/NK-cell Lymphoproliferative Diseases, Refractory/Relapsed EBV-related Hemophagocytic Lymphohistiocytosis · Beijing Children's Hospital | Not applicable | Recruiting | Mar 23, 2026 |
| A Study of LIVTENCITY (Maribavir) in Adults With Cytomegalovirus (CMV) Infection After Transplantation in South KoreaCytomegalovirus (CMV) · Takeda | — | Recruiting | Aug 15, 2024 |
| Pharmacokinetics of Drugs Administered to ChildrenPediatric ALL · Duke University | — | Recruiting | Mar 29, 2018 |
| Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell TransplantHematopoietic/Lymphoid Cancer, Accelerated Phase Chronic Myelogenous Leukemia · City of Hope Medical Center | — | Active, not recruiting | Sep 13, 2010 |
| Sep 27, 1991 | FoscavirNDA 20068 · New molecular entity | Clinigen Hlthcare | 20 | Marketed |
| May 31, 2005 | Foscarnet SodiumANDA 77174 | Hospira | 1 | Discontinued |
| Jan 29, 2021 | Foscarnet SodiumANDA 212483 | Fresenius Kabi USA | 0 | Marketed |
| Apr 21, 2021 | Foscarnet SodiumANDA 213001 | Gland | 0 | Marketed |
| Jun 5, 2023 | Foscarnet SodiumANDA 213807 | Avet Lifesciences | 0 | Marketed |
| Nov 29, 2023 | Foscarnet SodiumANDA 213987 | Sciecure | 0 | Marketed |
| Mar 1, 2024 | Foscarnet SodiumANDA 216602 | Amneal | 0 | Marketed |
| May 13, 2026 | Foscarnet SodiumANDA 220068 | Caplin | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Fresenius Kabi USA